Merz Pharma’s Xeomin authorised

Merz Pharma has received authorisation for Xeomin and it will be available for some healthcare professionals in the near future.

It is the first botulinum neurotoxin type A free of complexing proteins, a feat which has been achieved through employing unique filtering technology.

As well as managing blepharospasm, the treatment is also intended for aiding cervical dystonia and stroke spasticity of the upper limb – both of which can require high doses of neurotoxin for long periods of time.

This is thought to possibly increase the number of antibodies that form when it used with a high foreign protein load – which is why the filtering technology is an advantage in Xeomin.

Another benefit the product offers is the fact it can be stored at room temperature for up to three years.

Merz explained: “This improved shelf life greatly reduces the risk of a compromised storage temperature either during shipping, at the pharmacy or in a medical office.”

The German firm specialises in researching and marketing drugs to treat neurological and psychiatric diseases.